SCHEMBL7560227

SCHEMBL7560227

Cc1ccc(/C=N\NC(=O)c2[nH]c3ccccc3c2-c2ccccc2)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
ALDH1A1 P00352 5/20 0.61
ALPG P10696 1/20 0.61
LMNA P02545 5/20 0.56
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
GAA P10253 1/20 0.55
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54
RAB9A P51151 4/20 0.53
HPGD P15428 3/20 0.53
HTT P42858 1/20 0.53
PAX8 Q06710 2/20 0.52
KDM4E B2RXH2 2/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 2/20 0.51
TCF4 P15884 1/20 0.50
CTNNB1 P35222 1/20 0.50
TCF7L2 Q9NQB0 1/20 0.50
TUBB4A P04350 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7560230 1.00 MAPT (0.61) MAPTALDH1A1ALPGLMNAMEN1
SCHEMBL7561691 0.87 MAPT (0.58) MAPTALDH1A1ALPGLMNAMEN1
SCHEMBL7561687 0.87 MAPT (0.58) MAPTALDH1A1ALPGLMNAMEN1
SCHEMBL7559736 0.87 MAPT (0.65) MAPTALDH1A1ALPGLMNAMEN1
SCHEMBL7559734 0.87 MAPT (0.65) MAPTALDH1A1ALPGLMNAMEN1
SCHEMBL7560462 0.87 GAA (0.55) MAPTALDH1A1ALPGLMNAMEN1
SCHEMBL7560458 0.87 GAA (0.55) MAPTALDH1A1ALPGLMNAMEN1
SCHEMBL7534877 0.85 MEN1 (0.55) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL7561442 0.85 MEN1 (0.55) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL7567200 0.84 MAPT (0.75) MAPTALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885ALDH1A1 98/4885ALPG 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.